Sometimes good clinical data isn't enough to save a biotech stock. Fractyl Health Inc. (GUTS) found that out the hard way Thursday, with shares plunging more than 64% in premarket trading after the company suggested it might change how it's seeking FDA approval for its lead product.
The stock hit a 52-week low on massive volume—78.07 million shares traded compared to a typical 3.31 million average. So what spooked investors despite what looks like pretty solid clinical results?
Here's the situation: Fractyl announced six-month data from its REMAIN-1 trial testing Revita, a one-time minimally invasive endoscopic procedure designed to help patients maintain weight loss after they stop taking GLP-1 medications like Ozempic or Wegovy. The device works by remodeling the duodenal lining to restore healthy nutrient sensing and signaling that gets disrupted by chronic metabolic disease.
The FDA has already granted Revita Breakthrough Device designation for weight maintenance in patients discontinuing GLP-1 therapies, which sounds encouraging. But based on ongoing conversations with regulators and the safety data collected so far, Fractyl is now asking the FDA whether Revita could be reclassified under the De Novo pathway rather than going through the more demanding Premarket Approval process.
The De Novo pathway is designed for novel medical devices with low-to-moderate risk profiles and typically offers a more efficient, risk-based regulatory review. Translation: potentially faster approval, but the market seems nervous about the strategic pivot. The company expects FDA feedback on this potential pathway switch sometime in the second quarter of 2026.
The Clinical Data Looks Pretty Good
Putting the regulatory uncertainty aside for a moment, the actual trial results seem promising. In the prespecified efficacy population, patients treated with Revita regained 4.5% of their weight versus 7.5% in the sham control group at six months. That difference approached statistical significance with a p-value of 0.07, suggesting meaningful attenuation of the typical post-GLP-1 weight rebound.
The numbers get even more interesting when you look at the patients who responded best to GLP-1 drugs during the run-in period. Among the 20 participants who achieved above-median weight loss on GLP-1s, those treated with Revita regained just 4.2% of their weight compared to 13.3% in the sham group at six months. That represents roughly a 70% relative reduction in post-GLP-1 weight regain—a pretty substantial difference.
Beyond the scale, Revita-treated patients showed improvements in cardiometabolic markers. HDL cholesterol (the good kind) increased by 15.5 mg/dL versus just 3.9 mg/dL in the control group. The triglyceride-to-HDL ratio also improved, dropping by 0.2 in the Revita group while increasing by 0.4 in the sham arm. These changes suggest better overall metabolic regulation after stopping GLP-1 therapy.
There were behavioral benefits too. Patient-reported outcomes showed meaningful reductions in sweet-food cravings in the Revita group compared to controls—1.8 versus 3.4 on the measurement scale.
Safety Profile Holds Up
On the safety front, Revita continued demonstrating favorable tolerability through six months of follow-up. The company reported no treatment-related serious adverse events tied to the device or procedure, and no patients dropped out of the study due to adverse events. Between the three-month and six-month checkpoints, no new related adverse events emerged.
The company is expecting 12-month randomized data in the third quarter of 2026, which should provide a fuller picture of Revita's durability.
Price Action: GUTS stock traded at $0.644 in premarket Thursday, down 64.81% from the previous close.
